安得能微脂體注射劑5 毫克毫升(Onivyde) 醫療科技評估報告 | 合法藥品大搜索

ONIVYDE(irinotecan微脂體注射劑)適用於轉移性胰腺癌，合併5-fluorouracil和leucovorin治療曾接受過gemcitabine的患者。 用法用量. 請勿以ONIVYDE取代其他含有 ... Read More

Irinotecan liposome injection, 5mg/mL. 主管機關許可適應症Onivyde (irinotecan 微脂體注射劑) 適用於轉移性胰腺癌，合併. 5-fluorouracil 和leucovorin 治療曾接受 ... Read More

由 JE Frampton 著作 · 2020 · 被引用 4 次 — Liposomal irinotecan (nal-IRI; Onivyde®; also known as pegylated liposomal irinotecan) has been developed with the aim of maximising ... Read More

由 DE Baker 著作 · 2017 · 被引用 5 次 — Irinotecan liposome injection is indicated for use in conjunction with fluorouracil and leucovorin as second-line therapy of metastatic pancreatic cancer that has ... Read More

由 H Bien 著作 · 2016 — Liposomal encapsulated irinotecan, in combination with leucovorin-modulated fluorouracil, was found to significantly increase overall survival in patients who have ... Read More

由 T Macarulla 著作 · 2019 · 被引用 7 次 — Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI ... Read More

由 YN Lamb 著作 · 2017 · 被引用 38 次 — Liposomal irinotecan is a liposome-encapsulated formulation of the topoisomerase-1 inhibitor irinotecan, developed to overcome the pharmacological and clinical ... Read More

由 A Wang-Gillam 著作 · 2019 · 被引用 67 次 — Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is approved for patients with metastatic pancreatic ductal ... Read More

由 YY Su 著作 · 2020 · 被引用 4 次 — Liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI + 5-FU/LV) has shown to provide survival benefits for patients with ... Read More